Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
-
BUSINESS Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
-
BUSINESS Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
-
BUSINESS Operating Profit Ratio for Pharmaceutical Wholesales at 0.32%, Improved but Still in Low Range: Top 4 Wholesalers
May 15, 2012
-
BUSINESS Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda
May 15, 2012
-
REGULATORY Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
-
BUSINESS The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
-
BUSINESS “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
-
BUSINESS Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
-
ORGANIZATION Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
-
BUSINESS Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
-
BUSINESS OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
-
BUSINESS DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
-
ACADEMIA St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions
April 27, 2012
-
REGULATORY CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
-
BUSINESS Generics Aimed for Early Stage Sales of 10 Billion Yen, in the Black for Establishing Base: Daiichi Sankyo Espha President Yoshiwaka
April 25, 2012
-
BUSINESS Astellas Senior VP Sato Shares Plans to Market Gonax Within Current Structure, MRs Dedicated to Cancer “a Future Issue”
April 24, 2012
-
BUSINESS Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
-
ORGANIZATION JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
-
BUSINESS Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…